Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. the EURIKA study

José R. Banegas, Esther López-García, Jean Dallongeville, Eliseo Guallar, Julian P. Halcox, Claudio Borghi, Elvira L. Massó-González, Ogün Sazova, Joep Perk, Philippe Gabriel Steg, Guy De Backer, Fernando Rodríguez-Artalejo

Research output: Contribution to journalArticle

Abstract

Objective: To examine for the first time the achievement of lipoprotein treatment goals in patients with metabolic syndrome and lipid abnormalities who are at elevated cardiovascular risk in Europe. Methods: Cross-sectional study conducted in 2009-2010 in 12 European countries among outpatients aged ≥ 50 years free of clinical cardiovascular disease. We assessed achievement of American Diabetes Association/American College of Cardiology lipid treatment goals in those with metabolic syndrome at highest risk (diabetes plus ≥ 1 additional major cardiovascular risk factor beyond lipid abnormalities) or high risk (no diabetes but ≥ 2 additional major cardiovascular risk factors). Results: Among 1431 highest-risk patients, 64.6% (between-country range [BCR] 40-84.5%) were on lipid-lowering medication. Of them, 13.4% (BCR: 2.5-28.6%) had LDL-cholesterol <70 mg/dl, non-HDL-cholesterol <100 mg/dl, and apolipoprotein B <80 mg/dl. Among 832 high-risk patients, 38.7% BCR: 27.5-55.3%) were on lipid-lowering medication. Of them, 20.5% (BCR: 5.5-57.6%) had LDL-cholesterol <100 mg/dl, non-HDL-cholesterol <130 mg/dl, and apolipoprotein B <90 mg/dl. About 96% of highest-risk patients and 94% of high-risk patients were given at least one lifestyle advice (weight reduction, healthy diet, physical activity, no-smoking), but only 1.3% of the former and 4.9% of the latter reached all three lipid goals. Conclusion: There is a substantial gap between clinical guidelines and medical practice since only one in 5-7 patients met all treatment targets. Although most patients received lifestyle advice, the effectiveness of counseling was very low. Large between-country differences in outcomes suggest considerable room for improvement.

Original languageEnglish (US)
Pages (from-to)210-214
Number of pages5
JournalInternational Journal of Cardiology
Volume166
Issue number1
DOIs
StatePublished - Jun 5 2013

Fingerprint

Lipoproteins
Lipids
Apolipoproteins B
LDL Cholesterol
Life Style
Cholesterol
Reducing Diet
Practice Guidelines
Type 2 Diabetes Mellitus
Counseling
Outpatients
Cardiovascular Diseases
Therapeutics
Cross-Sectional Studies
Smoking
Exercise

Keywords

  • Cardiometabolic syndrome
  • Diabetes
  • Dyslipidemia
  • Europe
  • Goal
  • Primary prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. the EURIKA study. / Banegas, José R.; López-García, Esther; Dallongeville, Jean; Guallar, Eliseo; Halcox, Julian P.; Borghi, Claudio; Massó-González, Elvira L.; Sazova, Ogün; Perk, Joep; Steg, Philippe Gabriel; De Backer, Guy; Rodríguez-Artalejo, Fernando.

In: International Journal of Cardiology, Vol. 166, No. 1, 05.06.2013, p. 210-214.

Research output: Contribution to journalArticle

Banegas, JR, López-García, E, Dallongeville, J, Guallar, E, Halcox, JP, Borghi, C, Massó-González, EL, Sazova, O, Perk, J, Steg, PG, De Backer, G & Rodríguez-Artalejo, F 2013, 'Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. the EURIKA study', International Journal of Cardiology, vol. 166, no. 1, pp. 210-214. https://doi.org/10.1016/j.ijcard.2011.10.094
Banegas, José R. ; López-García, Esther ; Dallongeville, Jean ; Guallar, Eliseo ; Halcox, Julian P. ; Borghi, Claudio ; Massó-González, Elvira L. ; Sazova, Ogün ; Perk, Joep ; Steg, Philippe Gabriel ; De Backer, Guy ; Rodríguez-Artalejo, Fernando. / Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. the EURIKA study. In: International Journal of Cardiology. 2013 ; Vol. 166, No. 1. pp. 210-214.
@article{aae7275b8200439e88278327b600dd6e,
title = "Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. the EURIKA study",
abstract = "Objective: To examine for the first time the achievement of lipoprotein treatment goals in patients with metabolic syndrome and lipid abnormalities who are at elevated cardiovascular risk in Europe. Methods: Cross-sectional study conducted in 2009-2010 in 12 European countries among outpatients aged ≥ 50 years free of clinical cardiovascular disease. We assessed achievement of American Diabetes Association/American College of Cardiology lipid treatment goals in those with metabolic syndrome at highest risk (diabetes plus ≥ 1 additional major cardiovascular risk factor beyond lipid abnormalities) or high risk (no diabetes but ≥ 2 additional major cardiovascular risk factors). Results: Among 1431 highest-risk patients, 64.6{\%} (between-country range [BCR] 40-84.5{\%}) were on lipid-lowering medication. Of them, 13.4{\%} (BCR: 2.5-28.6{\%}) had LDL-cholesterol <70 mg/dl, non-HDL-cholesterol <100 mg/dl, and apolipoprotein B <80 mg/dl. Among 832 high-risk patients, 38.7{\%} BCR: 27.5-55.3{\%}) were on lipid-lowering medication. Of them, 20.5{\%} (BCR: 5.5-57.6{\%}) had LDL-cholesterol <100 mg/dl, non-HDL-cholesterol <130 mg/dl, and apolipoprotein B <90 mg/dl. About 96{\%} of highest-risk patients and 94{\%} of high-risk patients were given at least one lifestyle advice (weight reduction, healthy diet, physical activity, no-smoking), but only 1.3{\%} of the former and 4.9{\%} of the latter reached all three lipid goals. Conclusion: There is a substantial gap between clinical guidelines and medical practice since only one in 5-7 patients met all treatment targets. Although most patients received lifestyle advice, the effectiveness of counseling was very low. Large between-country differences in outcomes suggest considerable room for improvement.",
keywords = "Cardiometabolic syndrome, Diabetes, Dyslipidemia, Europe, Goal, Primary prevention",
author = "Banegas, {Jos{\'e} R.} and Esther L{\'o}pez-Garc{\'i}a and Jean Dallongeville and Eliseo Guallar and Halcox, {Julian P.} and Claudio Borghi and Mass{\'o}-Gonz{\'a}lez, {Elvira L.} and Og{\"u}n Sazova and Joep Perk and Steg, {Philippe Gabriel} and {De Backer}, Guy and Fernando Rodr{\'i}guez-Artalejo",
year = "2013",
month = "6",
day = "5",
doi = "10.1016/j.ijcard.2011.10.094",
language = "English (US)",
volume = "166",
pages = "210--214",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. the EURIKA study

AU - Banegas, José R.

AU - López-García, Esther

AU - Dallongeville, Jean

AU - Guallar, Eliseo

AU - Halcox, Julian P.

AU - Borghi, Claudio

AU - Massó-González, Elvira L.

AU - Sazova, Ogün

AU - Perk, Joep

AU - Steg, Philippe Gabriel

AU - De Backer, Guy

AU - Rodríguez-Artalejo, Fernando

PY - 2013/6/5

Y1 - 2013/6/5

N2 - Objective: To examine for the first time the achievement of lipoprotein treatment goals in patients with metabolic syndrome and lipid abnormalities who are at elevated cardiovascular risk in Europe. Methods: Cross-sectional study conducted in 2009-2010 in 12 European countries among outpatients aged ≥ 50 years free of clinical cardiovascular disease. We assessed achievement of American Diabetes Association/American College of Cardiology lipid treatment goals in those with metabolic syndrome at highest risk (diabetes plus ≥ 1 additional major cardiovascular risk factor beyond lipid abnormalities) or high risk (no diabetes but ≥ 2 additional major cardiovascular risk factors). Results: Among 1431 highest-risk patients, 64.6% (between-country range [BCR] 40-84.5%) were on lipid-lowering medication. Of them, 13.4% (BCR: 2.5-28.6%) had LDL-cholesterol <70 mg/dl, non-HDL-cholesterol <100 mg/dl, and apolipoprotein B <80 mg/dl. Among 832 high-risk patients, 38.7% BCR: 27.5-55.3%) were on lipid-lowering medication. Of them, 20.5% (BCR: 5.5-57.6%) had LDL-cholesterol <100 mg/dl, non-HDL-cholesterol <130 mg/dl, and apolipoprotein B <90 mg/dl. About 96% of highest-risk patients and 94% of high-risk patients were given at least one lifestyle advice (weight reduction, healthy diet, physical activity, no-smoking), but only 1.3% of the former and 4.9% of the latter reached all three lipid goals. Conclusion: There is a substantial gap between clinical guidelines and medical practice since only one in 5-7 patients met all treatment targets. Although most patients received lifestyle advice, the effectiveness of counseling was very low. Large between-country differences in outcomes suggest considerable room for improvement.

AB - Objective: To examine for the first time the achievement of lipoprotein treatment goals in patients with metabolic syndrome and lipid abnormalities who are at elevated cardiovascular risk in Europe. Methods: Cross-sectional study conducted in 2009-2010 in 12 European countries among outpatients aged ≥ 50 years free of clinical cardiovascular disease. We assessed achievement of American Diabetes Association/American College of Cardiology lipid treatment goals in those with metabolic syndrome at highest risk (diabetes plus ≥ 1 additional major cardiovascular risk factor beyond lipid abnormalities) or high risk (no diabetes but ≥ 2 additional major cardiovascular risk factors). Results: Among 1431 highest-risk patients, 64.6% (between-country range [BCR] 40-84.5%) were on lipid-lowering medication. Of them, 13.4% (BCR: 2.5-28.6%) had LDL-cholesterol <70 mg/dl, non-HDL-cholesterol <100 mg/dl, and apolipoprotein B <80 mg/dl. Among 832 high-risk patients, 38.7% BCR: 27.5-55.3%) were on lipid-lowering medication. Of them, 20.5% (BCR: 5.5-57.6%) had LDL-cholesterol <100 mg/dl, non-HDL-cholesterol <130 mg/dl, and apolipoprotein B <90 mg/dl. About 96% of highest-risk patients and 94% of high-risk patients were given at least one lifestyle advice (weight reduction, healthy diet, physical activity, no-smoking), but only 1.3% of the former and 4.9% of the latter reached all three lipid goals. Conclusion: There is a substantial gap between clinical guidelines and medical practice since only one in 5-7 patients met all treatment targets. Although most patients received lifestyle advice, the effectiveness of counseling was very low. Large between-country differences in outcomes suggest considerable room for improvement.

KW - Cardiometabolic syndrome

KW - Diabetes

KW - Dyslipidemia

KW - Europe

KW - Goal

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=84877726164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877726164&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2011.10.094

DO - 10.1016/j.ijcard.2011.10.094

M3 - Article

VL - 166

SP - 210

EP - 214

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -